Results of a randomized, double-blind, placebo-controlled studyadministering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy

McCluskey, Dennis; Touger, Michael; Melis, Robert; Schleusener, Debra S.

doi:10.1016/j.clinthera.2004.11018

Cited by 17 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, favourable effects of RSG/GLIM FDC regimens on markers of insulin sensitivity, free fatty acids and adiponectin are consistent with those previously reported with RSG treatment. These results support previous findings of TZDs in combination with GLIM [38–41].…”

Section: Discussionsupporting

confidence: 93%

Initial treatment with fixed‐dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes

Chou

Palmer

Jones

et al. 2008

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Initial treatment with fixed‐dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes

Chou

Palmer

Jones

et al. 2008

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Combination therapy with rosiglitazone plus glimepiride versus rosiglitazone plus placebo was evaluated in a multicenter, double-blind, placebo-controlled study 34. A target HbA 1c of <7% was achieved in the glimepiride group and no significant difference was observed in adverse events between the two groups.…”

Section: Comparison With Thiazolidinedionesmentioning

confidence: 99%

Glimepiride: evidence-based facts, trends, and observations

Basit¹,

Riaz²,

Fawwad³

2012

VHRM

View full text Add to dashboard Cite

Type 2 diabetes mellitus is characterized by insulin resistance and progressive β cell failure; therefore, β cell secretagogues are useful for achieving sufficient glycemic control. Glimepiride is a second-generation sulfonylurea that stimulates pancreatic β cells to release insulin. Additionally, is has been shown to work via several extra pancreatic mechanisms. It is administered as monotherapy in patients with type 2 diabetes mellitus in whom glycemic control is not achieved by dietary and lifestyle modifications. It can also be combined with other antihyperglycemic agents, including metformin and insulin, in patients who are not adequately controlled by sulfonylureas alone. The effective dosage range is 1 to 8 mg/day; however, there is no significant difference between 4 and 8 mg/day, but it should be used with caution in the elderly and in patients with renal or hepatic disease. In clinical studies, glimepiride was generally associated with lower risk of hypoglycemia and less weight gain compared to other sulfonylureas. Glimepiride use may be safer in patients with cardiovascular disease because of its lack of detrimental effects on ischemic preconditioning. It is effective in reducing fasting plasma glucose, post-prandial glucose, and glycosylated hemoglobin levels and is a useful, cost-effective treatment option for managing type 2 diabetes mellitus.

show abstract

“…More patients in the glimepiride group achieved the HbA1c target of ≤7% (60% vs 14%; p < 0.01). There were no significant differences in the rate or type of adverse events between groups, and no episodes of severe hypoglycemia occurred with either treatment (McCluskey et al 2004). It needs to be pointed out, however, that the inclusion criteria of the patients in this trial may have potentially resulted in selection of pharmacological non-responders to rosiglitazone therapy, but unfortunately no pharmacogenetic characterization is provided for the trial participants in this manuscript.…”

Section: Studies Comparing the Rosiglitazone/su Combination Vs Su Monmentioning

confidence: 93%

“…In accordance with the current treatment guidelines, rosiglitazone was added to a SU drug in all aforementioned trials, but McCluskey et al (2004) investigated the converse situation. A total of 40 patients who failed on rosiglitazone mono-therapy were treated with additional glimepiride vs placebo for 26 weeks.…”

Section: Studies Comparing the Rosiglitazone/su Combination Vs Su Monmentioning

confidence: 99%

Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination

Pfützner¹,

Wilhelm²,

Forst³

2007

Vascular Health and Risk Management

View full text Add to dashboard Cite

Type 2 diabetes has become a major burden to the health care systems worldwide. Among the drugs approved for this indication, glimepiride and rosiglitazone have gained substantial importance in routine use. While glimepiride stimulates β-cell secretion and leads to reduction of blood glucose values, rosiglitazone activates PPARγ and improves insulin resistance, at the vascular and metabolically active cells. Therefore, the combination of the two drugs may be an interesting approach to improve glycemic control and lower cardiovascular risk. A fi xed combination of both drugs has been approved for clinical use in the US and EU. The combination of glimepiride and rosiglitazone is generally well tolerated and the use of a fi xed combination may lead to improved adherence of the patients to their therapy. The purpose of this review is to evaluate the clinical data that have been published on this combination, appearing to represent a convenient way to obtain therapeutic targets in patients with type 2 diabetes mellitus.

show abstract

Results of a randomized, double-blind, placebo-controlled studyadministering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy

Cited by 17 publications

References 13 publications

Initial treatment with fixed‐dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes

Initial treatment with fixed‐dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes

Glimepiride: evidence-based facts, trends, and observations

Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination

Contact Info

Product

Resources

About